148 related articles for article (PubMed ID: 20084020)
1. Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas.
Elsir T; Eriksson A; Orrego A; Lindström MS; Nistér M
J Neuropathol Exp Neurol; 2010 Feb; 69(2):129-38. PubMed ID: 20084020
[TBL] [Abstract][Full Text] [Related]
2. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
3. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
Erdamar S; Bagci P; Oz B; Dirican A
J BUON; 2006; 11(2):213-6. PubMed ID: 17318973
[TBL] [Abstract][Full Text] [Related]
4. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.
Geiger KD; Stoldt P; Schlote W; Derouiche A
Am J Pathol; 2000 Dec; 157(6):1785-93. PubMed ID: 11106550
[TBL] [Abstract][Full Text] [Related]
5. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
6. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
7. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
8. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
[TBL] [Abstract][Full Text] [Related]
9. Expression and release of CD14 in astrocytic brain tumors.
Deininger MH; Meyermann R; Schluesener HJ
Acta Neuropathol; 2003 Sep; 106(3):271-7. PubMed ID: 12835948
[TBL] [Abstract][Full Text] [Related]
10. Does vasculogenic mimicry exist in astrocytoma?
Yue WY; Chen ZP
J Histochem Cytochem; 2005 Aug; 53(8):997-1002. PubMed ID: 15923371
[TBL] [Abstract][Full Text] [Related]
11. Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors.
Blümcke I; Müller S; Buslei R; Riederer BM; Wiestler OD
Acta Neuropathol; 2004 Aug; 108(2):89-96. PubMed ID: 15146346
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) receptor neuropilin-1's distribution in astrocytic tumors.
Broholm H; Laursen H
APMIS; 2004; 112(4-5):257-63. PubMed ID: 15233640
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of epidermal growth factor receptor protein and c-erbB-2 oncoprotein in human astrocytic tumors. An immunohistochemical study.
Dietzmann K; von Bossanyi P
Zentralbl Pathol; 1994 Nov; 140(4-5):335-41. PubMed ID: 7826981
[TBL] [Abstract][Full Text] [Related]
14. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K
Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609
[TBL] [Abstract][Full Text] [Related]
15. Microvessel density in brain tumors.
Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Papadakis N; Varakis I
Anticancer Res; 1997; 17(6D):4747-53. PubMed ID: 9494601
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules.
Liu X; Chen N; Wang X; He Y; Chen X; Huang Y; Yin W; Zhou Q
J Neuropathol Exp Neurol; 2006 Sep; 65(9):905-13. PubMed ID: 16957584
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of tumour vessels in cytological squash smears of astrocytic tumours.
Sato S; Sato Y; Marutsuka K; Takeshima H; Asada Y
Cytopathology; 2011 Oct; 22(5):313-7. PubMed ID: 21039979
[TBL] [Abstract][Full Text] [Related]
18. Geminin: a good prognostic factor in high-grade astrocytic brain tumors.
Shrestha P; Saito T; Hama S; Arifin MT; Kajiwara Y; Yamasaki F; Hidaka T; Sugiyama K; Kurisu K
Cancer; 2007 Mar; 109(5):949-56. PubMed ID: 17262828
[TBL] [Abstract][Full Text] [Related]
19. Tenascin expression in astrocytomas correlates with angiogenesis.
Zagzag D; Friedlander DR; Miller DC; Dosik J; Cangiarella J; Kostianovsky M; Cohen H; Grumet M; Greco MA
Cancer Res; 1995 Feb; 55(4):907-14. PubMed ID: 7531617
[TBL] [Abstract][Full Text] [Related]
20. Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression.
Benzil DL; Finkelstein SD; Epstein MH; Finch PW
Cancer Res; 1992 May; 52(10):2951-6. PubMed ID: 1316231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
